Better Health for All

Kura Oncology's core business is the discovery and development of precision medicines for cancer, including blood cancers, solid tumors, AML, head and neck squamous cell carcinoma, and non-small cell lung cancer.

One of its investigational drugs, Komzifti, received FDA approval. The company has no products with significant negative health impacts. However, Komzifti was subsequently voluntarily withdrawn from the market due to a safety signal, indicating a notable safety incident. Kura offers a Patient Assistance Program where eligible, commercially insured patients may pay as little as $0 per month, and uninsured patients may qualify for free medicine. The company's Patient Assistance Program is available to eligible patients without insurance. Kura Oncology is a clinical-stage biopharmaceutical company committed to precision medicines for cancer treatment. Kura is participating in the PedAL initiative, a global master clinical trial for Pediatric Acute Leukemia. The company provides grant support for medical education programs to enhance healthcare professionals' ability in diagnosing and treating patients in its therapeutic areas of interest. Kura conducts clinical studies to assess the safety and efficacy of investigational drugs, with ziftomenib demonstrating an encouraging safety profile in a Phase 1 study.

Fair Money & Economic Opportunity

Kura Oncology, Inc. is a biopharmaceutical company focused on cancer treatment.

Its core business does not involve offering lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for financial services, and product simplicity for financial products, are not applicable to the company's operations. While the company offers patient assistance programs for drug access, these are not financial services as defined by the rubric.

Fair Pay & Worker Respect

In 2024, the company's CEO to median employee pay ratio was 16:1.

This is based on the CEO's total compensation of $6,239,098 and the median employee pay of $395,686.

Honest & Fair Business

Kura Oncology, Inc. operates a confidential and anonymous financial concern hotline, which is mandated by the SEC for complaints related to accounting, internal accounting controls, or auditing matters.

The hotline supports secure web form and phone submissions and provides a confirmation code for tracking message status. However, there is no evidence regarding the independence of investigation processes, training frequency, or the policy's overall scope.

Kind to Animals

Kura Oncology conducts in vivo animal testing, specifically using mouse models for xenograft experiments in cancer research.

These experiments, including cell line-derived and patient-derived xenografts, are performed under protocols approved by Institutional Animal Care and Use Committees (IACUC) at institutions like the University of California, San Diego and Crown Bioscience. The studies adhere to regulations from organizations such as the Association for Assessment and Accreditation of Laboratory Animal Care. While specific total animal numbers are not provided, the company uses n=10 mice per group in some cell line-derived xenograft studies and n=3 or n=5 mice per group in patient-derived xenograft studies. One study mentioned the use of mouse models in leukemia research, with a median survival time of 42 days for control mice and a 20-day treatment duration for MI-3454.

No War, No Weapons

No relevant data could be extracted from the provided article to assess Kura Oncology, Inc. against the 'No War, No Weapons' ethical value.

The article explicitly stated that its content was unavailable, preventing any evaluation of the company's performance across the specified KPIs.

Planet-Friendly Business

The provided articles do not contain specific, quantitative data points for any of the environmental performance KPIs. Article 0 details philanthropic contributions to community organizations, which are not directly related to Kura Oncology's environmental stewardship, emissions, energy use, waste, or climate-related financial disclosures.

Article 1 explicitly states that it does not contain quantitative data relevant to KURA.US's sustainability performance.

Respect for Cultures & Communities

Kura Oncology pledged a $250,000 contribution to Life Science Cares (LSC) for educational initiatives in San Diego and Greater Boston.

This funding will be distributed as grant funding to community-based organizations providing access to basic needs, education, and opportunity. Based on the company's 2023 revenue of $345.8 million, this donation represents approximately 0.07% of revenue. While the rubric uses 'non-core revenue', without that specific figure, using total revenue as a proxy, 0.07% falls below the 1-3% threshold for the -50 tier.

Zero Waste & Sustainable Products

The provided articles do not contain specific, quantifiable data points that directly map to the quantitative thresholds of the KPIs in the 'Zero Waste & Sustainable Products' rubric. While articles mention 'over 6 tons of waste recycled and composted' in 2024, this is a total weight, not a percentage of waste diverted, which is required by the rubric.

Statements about commitment to responsible waste management are not specific, measurable initiatives. The B Corp designation is a general certification and does not provide specific metrics for zero waste. No data was found for product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste audit frequency, hazardous waste management, product durability, repairability, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education. The absence of information regarding violations or certifications does not constitute evidence for scoring.